Logo Image
  • News
  • Watch
  • Journals
  • Conferences
  • Events
  • Resources
  • CE
  • About AJMC
  • Subscribe

Mantle Cell Lymphoma

Latest News

An expert featured in this series.
December 23rd 2025
Duration of Response With Sonrotoclax Vs Current Therapies for MCL

At ASH 2025, sonrotoclax demonstrated encouraging response rates and a favorable safety profile as a single-agent BCL2 inhibitor in heavily pretreated, largely refractory mantle cell lymphoma.

An expert featured in this series.
December 23rd 2025

Sonrotoclax Shows Promising Efficacy, Improved Tolerability in Heavily Pretreated MCL

Among the 20 patients evaluable for treatment response, all achieved complete response, and 95% reached undetectable minimal residual disease at a threshold of 10⁻⁶. | Image credit: Zhanna - stock.adobe.com
December 19th 2025

Experimental Triplet Regimen Shows Early Promise in High-Risk MCL

The new study explores a different paradigm—one that replaces chemotherapy with targeted agents while using MRD monitoring. | Image credit: David A Litman - stock.adobe.com
December 9th 2025

MRD-Guided Therapy Shows Promise as a Time-Limited Frontline Strategy for MCL

FDA icon on screen surrounded by medical icons | Image credit: wladimir1804 - stock.adobe.com
December 1st 2025

Sonrotoclax Receives FDA Priority Review for R/R Mantle Cell Lymphoma